Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on ...
Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates. It arises from chronic liver diseases, including hepatitis B or C infections, ...
Sclerosteosis is a rare genetic disorder that causes excessive bone growth, leading to life-altering complications, including hearing loss and facial paralysis. In a promising new breakthrough, ...
WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis. Longitudinal clinical validation of the ...
Morning Overview on MSN
Researchers find some cancer drugs work differently than their stated targets
As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...
Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results